Cancer Target and Antibody
TRA-1-60
Since 2012, CureMeta has generated compelling preclinical research data showing TRA-1-60 is present on the cell surface of cancer cells in aggressive and metastatic tumors. Nine independent research groups around the world have published scientific studies confirming TRA-1-60 as an important tumor marker in many kinds of cancer.
To the left is a picture of gastric cancer stained for TRA-1-60 (brown color indicates the presence of the molecule).
The graph on the right shows TRA-1-60 staining pattern in 28 of 34 cases of metastatic gastric cancer, and no staining in normal gastric specimens without cancer.
CM-09
Bstrongximab is a human/mouse chimeric IgG1 antibody with high specificity and high affinity to TRA-1-60. Our CM-09 drug is an antibody-drug-conjugate with the toxin Mono-Methyl Auristatin E attached to the Bstrongximab antibody. CM-09 is internalized into the cancer cell where the toxin is released causing cell death. CM-09 binds only to cancer cells and not normal cells, thus providing a highly specific targeted mechanism of action. Our preclinical research shows CM-09 to be a first-in-class cancer drug with high potency and killing efficacy for a number of difficult-to-treat cancers.
